Acelyrin, Concentra
Acelyrin Stock Jumps on Concentra Acquisition Interest
Shares of Acelyrin climbed after the company said it has received an unsolicited indication of interest from Concentra Biosciences for an acquisition at $3 a share. The stock was up 14% at $2.48 in premarket trading. Shares had fallen 31% year to date when the market closed Thursday.
Here's how an activist investor is threatening a Peninsula drug maker's merger plans. And the drama introduces a potential ...
As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...
On February 6, 2025, ACELYRIN announced an agreement to merge with Alumis Inc. (Nasdaq: ALMS) in an all-stock transaction. The transaction is expected to close in the second quarter of 2025, subject ...
Alumis and Acelyrin have announced a definitive merger agreement, which will result in an all-stock transaction, creating a late-stage clinical biopharma company. The merged company will focus on ...
Tang Capital's Concentra Biosciences offers to buy Acelyrin for $3/share, challenging planned Alumis merger. Concentra would ...
Agoura Hills-based biotech firm Acelyrin Inc. agreed to merge with San Francisco-based Alumis Inc. in a deal valued at $320 ...
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative ...
The interest from Concentra Biosciences includes an offer to purchase all outstanding shares of ACELYRIN at $3.00 each, plus a contingent value right tied to 80% of net proceeds from potential future ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback